There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Globus Medical (GMED – Research Report) and Zimmer Biomet Holdings (ZBH – Research Report) with bullish sentiments.

Globus Medical (GMED)

In a report released today, Jason Wittes from Roth MKM maintained a Buy rating on Globus Medical, with a price target of $115.00. The company’s shares closed last Thursday at $87.95, close to its 52-week high of $94.93.

According to TipRanks.com, Wittes is a 4-star analyst with an average return of 8.7% and a 55.4% success rate. Wittes covers the Healthcare sector, focusing on stocks such as Monogram Orthopaedics Inc, TriSalus Life Sciences, and Zimmer Biomet Holdings.

Currently, the analyst consensus on Globus Medical is a Moderate Buy with an average price target of $98.92, representing a 7.0% upside. In a report released yesterday, Stifel Nicolaus also reiterated a Buy rating on the stock with a $92.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Zimmer Biomet Holdings (ZBH)

JMP Securities analyst David Turkaly maintained a Buy rating on Zimmer Biomet Holdings today and set a price target of $140.00. The company’s shares closed last Thursday at $102.69, close to its 52-week low of $100.67.

According to TipRanks.com, Turkaly is a 1-star analyst with an average return of -2.0% and a 39.8% success rate. Turkaly covers the Healthcare sector, focusing on stocks such as OrthoPediatrics, Globus Medical, and Apyx Medical.

Currently, the analyst consensus on Zimmer Biomet Holdings is a Hold with an average price target of $123.00, implying a 18.3% upside from current levels. In a report issued on January 28, BTIG also maintained a Buy rating on the stock with a $126.00 price target.

Read More on GMED: